Please note: This review reflects information we gathered on the date it was researched and may now be out of date. Providers frequently change their pricing, plans, medications, and policies. Any ratings, reviews, and customer feedback are gathered from publicly available online sources and may have since changed or no longer be accurate. Always do your own research and confirm the latest details directly with the provider before making any decision.
Direct Meds Review
An in-depth look at Direct Meds — a compounded GLP-1 telehealth platform. We are publishing this one with its regulatory record first, because the FDA issued it a warning letter in September 2025 concerning the exact products a reader of this page would be buying.
Regulatory notice: FDA warning letter, 9 September 2025
The FDA issued a warning letter to directmeds.com, Inc. dba DirectMeds on 9 September 2025 (reference 716822). After reviewing directmeds.com in August 2025, the FDA found claims concerning its compounded semaglutide and tirzepatide products to be false or misleading, rendering those products misbranded under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act.The letter is publicly available in the FDA's warning letter database under that reference number, and we would encourage you to read it before purchasing.
We have reduced our rating from 4.5 to 3.2to reflect this. This review was originally published before we checked the FDA's enforcement record, and we would rather say so than quietly restate history. A warning letter of this kind concerns how a product was marketed or labelled — it is not a finding that the medication itself is unsafe — but it does mean the claims on the provider's own site warrant scepticism.
Direct Meds
FDA Warning LetterDirect Meds is a telehealth platform selling compounded semaglutide and tirzepatide to US patients. It positions itself on affordability, convenience and speed, with the standard model for this category: an online intake, review by a licensed provider, and medication shipped from a compounding pharmacy.
The reason this review leads with a red box is that the FDA has formally found its marketing wanting. In September 2025 the agency issued Direct Meds a warning letter after reviewing its website, concluding that claims about its compounded semaglutide and tirzepatide were false or misleading and that the products were therefore misbranded. That is a matter of public record and it is the single most useful thing a prospective customer can know.
To be proportionate: this is the most common enforcement action in the category, and roughly a dozen providers listed on this site have received one. The typical finding is a platform implying its compounded product is equivalent to the FDA-approved drug, or putting its own branding on a vial it did not compound. It is not a finding that the medication harmed anyone. But it does mean the claims on the company's own website have been judged unreliable by the regulator, which is a poor starting point for trust.
We were unable to verify current pricing directly when checking on 29 July 2026, so this review does not quote figures we cannot stand behind. Get your price, at your target dose, in writing before paying — and ask which pharmacy actually compounds your prescription, since that was central to the FDA's concern across this whole wave of letters.
Affiliate disclosure: GLP1Drugs.org earns a commission if you sign up through the links on this page, and this is one of the higher-paying weight-loss offers we carry. We have led the page with the FDA warning letter anyway.
See Direct Meds For YourselfOur Top Recommended Provider: CoreAge Rx
After reviewing dozens of GLP-1 telehealth providers, CoreAge Rx is the one we recommend most. CoreAge Rx is one of our partners — read on for why we recommend them:
Flat-Rate Pricing
Same cost at every dose level — no price jumps as you titrate up.
Verified Pharmacies
US-licensed physicians and NABP-verified 503A compounding pharmacies you can trust.
Everything Included
Medication, supplies, free shipping, and ongoing clinical support — no hidden fees.
Active Community of Members
Ask questions, share progress, and get answers from other patients on the same journey — alongside ongoing clinical support from your care team.
Sept 2025
FDA Warning Letter
716822
Letter Reference
1
State Excluded (AR)
No
FDA-Approved Medication
How the FDA Letters Compare
Direct Meds is not alone. This is how its letter sits against others held by providers reviewed on this site.
| Provider | Letter | Date | Nature of finding | Our rating |
|---|---|---|---|---|
| Direct Meds | 716822 | 9 Sep 2025 | Misleading claims re compounded GLP-1s | 3.2 |
| Remedy Meds | 716830 | 9 Sep 2025 | Misleading claims re compounded GLP-1s | 3.2 |
| Hims | 716567 | 9 Sep 2025 | “Same active ingredient as Ozempic” claims | 3.2 |
| Bliv | 721479 | 20 Feb 2026 | Own branding on label implying it compounded | 3.2 |
| Strut Health | 721448 | 20 Feb 2026 | Misleading claims, plus D+ BBB grade | 2.9 |
| Empower Pharmacy | 700964 | 2 Apr 2025 | Insanitary sterile compounding conditions | 2.8 |
The pattern matters more than any single row. An enforcement letter about marketing claims is common enough in this category that treating it as disqualifying would rule out much of the market — but it is a reason to verify everything you are told rather than take the website at face value. The Empower row is the exception: that one concerns manufacturing quality, which is a different and more serious thing.
What's Included
Compounded Semaglutide
The active ingredient in Ozempic and Wegovy, prepared by a compounding pharmacy — not FDA-approved and not the branded product
Compounded Tirzepatide
The dual GIP/GLP-1 agonist found in Mounjaro and Zepbound, in compounded form
Online Intake
A digital intake reviewed by a licensed provider, with prescribing subject to approval rather than guaranteed
Home Delivery
Medication shipped directly to the patient
Ongoing Support
Follow-up care through the platform
Pricing Not Verified
We could not confirm current published pricing when checking on 29 July 2026, so we are not quoting figures
Pros & Cons
Pros
- ✓Offers both compounded semaglutide and tirzepatide
- ✓Standard fully-online process with home delivery and no insurance requirement
- ✓Available in 49 states — only Arkansas is excluded, a narrower restriction than many competitors
- ✓Prescribing goes through a licensed provider rather than direct sale
Cons
- ✕Received an FDA warning letter on 9 September 2025 over false or misleading claims about its compounded semaglutide and tirzepatide
- ✕The FDA found those products misbranded under sections 502(a) and 502(bb) of the FDCA
- ✕We could not verify current pricing from the company's own site, so cost transparency is poor from a shopper's perspective
- ✕Compounded medications are not FDA-approved or evaluated by the FDA for safety, effectiveness or quality
- ✕Not available in Arkansas
- ✕Several better-documented providers on this site sit at comparable prices without an enforcement letter
Our Verdict
3.2 / 5 — a functioning compounded GLP-1 platform carrying a September 2025 FDA warning letter for misleading claims about the exact products it sells, with pricing we could not verify.
Rated consistently with the other providers on this site holding the same kind of enforcement letter. Direct Meds does what the category does — compounded semaglutide and tirzepatide, online intake, home delivery, only Arkansas excluded — and the FDA finding concerns its marketing rather than any harm from the medication. But two things count against it for a buyer: a regulator has formally judged its product claims misleading, and we could not verify what it charges. Both are solvable by asking direct questions before you pay. If you would rather not have to, several comparable providers reviewed here have no letter against them.
See Direct Meds For YourselfFrequently Asked Questions
Did Direct Meds get an FDA warning letter?
Yes. The FDA issued a warning letter to directmeds.com, Inc. dba DirectMeds on 9 September 2025, reference 716822. After reviewing the company's website in August 2025, the agency concluded that claims about its compounded semaglutide and tirzepatide products were false or misleading, making those products misbranded under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. You can read the letter in the FDA's warning letter database under that reference number.
Does that mean the medication is dangerous?
No, and it is important to be precise. The letter concerns marketing claims, not the safety of the drug that arrives. What it does mean is that a federal regulator formally judged the company's own statements about its products to be misleading — so the claims on its website are not a reliable basis for your decision. Verify independently: which pharmacy compounds it, what your actual total cost is, and what happens if you stop.
How much does Direct Meds cost?
We could not verify current pricing from the company's own site when checking on 29 July 2026, and we do not publish figures we cannot stand behind. Ask for your total monthly cost at your target dose — not the introductory rate — in writing before paying, including shipping and any consultation fee.
Which states is Direct Meds not available in?
This offer is not available in Arkansas. That is a narrower exclusion than most GLP-1 telehealth providers, several of which exclude ten or more states.
Should I use Direct Meds?
Only with your eyes open, and we would compare it carefully first. Several providers reviewed on this site offer compounded semaglutide and tirzepatide at comparable prices without an FDA enforcement letter — Enhance.MD and Oak among them. If you do proceed, ask which compounding pharmacy fills your prescription and get the answer in writing, because platform-branded labelling that obscures the actual compounder is exactly what this wave of FDA letters was about.
What are the side effects?
Commonly nausea, vomiting, diarrhoea and constipation, usually worst during dose escalation. More serious risks associated with GLP-1 receptor agonists include pancreatitis and gallbladder disease, and in animal studies thyroid C-cell tumours. These medications are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 and should not be used in pregnancy. Discuss your history with a licensed clinician.
Considering Direct Meds?
Read FDA warning letter 716822 first, then get your price and your compounding pharmacy's name in writing before paying.
See Direct Meds For YourselfCompare Other GLP-1 Providers
See how other telehealth providers stack up.
Amazon One Medical
Brand-Name, No CompoundingFDA-approved Wegovy, Zepbound and Foundayo from $149/month cash, $25 with insurance and $50/month for eligible Medicare members — the first mainstream route to approved medication at prices that compete with compounded. We earn no commission from it
Read Review →Boston Medical Group
Top RatedEstablished telehealth provider with physician oversight and transparent pricing
Read Review →BeyondMD
Top RatedBoard-certified physician-led care with comprehensive medical oversight
Read Review →GoodRx Care
Trusted BrandTelehealth platform from GoodRx with transparent pricing and established trust
Read Review →Mochi Health
Obesity Medicine SpecialistsBoard-certified obesity medicine specialists with both brand-name and compounded GLP-1 options
Read Review →LifeMD
Top RatedPublicly traded telehealth company with comprehensive health platform and competitive pricing
Read Review →Medical Disclaimer: This page is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved and are not evaluated by the FDA for safety, effectiveness or quality. GLP-1 medications commonly cause nausea, vomiting, diarrhoea and constipation and carry risks including pancreatitis and gallbladder disease; they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2, and should not be used in pregnancy. Prescribing is subject to provider approval and is not guaranteed. Always consult a qualified healthcare provider before starting any new medication.
Regulatory Note: FDA issued warning letter 716822 to directmeds.com, Inc. dba DirectMeds on 9 September 2025 concerning false or misleading claims about its compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the FDCA. The letter is publicly available in the FDA warning letter database. This offer is not available in Arkansas.
Affiliate Disclosure: This site may receive compensation from affiliate partners, including Direct Meds. This does not influence our editorial content or review ratings.